Higher survival rates of chronic hemodialysis patients on anti-hypertensive drugs

Nephron - Clinical Practice

Volumn 113, Issue 3, 2009, Pages

  Iseki, K ^a   Shoji, T ^a   Nakai, S ^a   Watanabe, Y ^a   Akiba, T ^a   Tsubakihara, Y ^a  

^a UNIVERSITY HOSPITAL OF THE RYUKYUS   (Japan)

Author keywords

Cardiovascular disease; Chronic hemodialysis; Hypertension; Survival

Indexed keywords

ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR;

ADULT; ANTIHYPERTENSIVE THERAPY; ARTICLE; CONTROLLED STUDY; DIABETES MELLITUS; DIASTOLIC BLOOD PRESSURE; FEMALE; HEMODIALYSIS PATIENT; HUMAN; HYPERTENSION; JAPAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; PRESCRIPTION; PRIORITY JOURNAL; SURVIVAL RATE; SYSTOLIC BLOOD PRESSURE;

AGED; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; FEMALE; HUMANS; HYPERTENSION; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; REGISTRIES; RENAL DIALYSIS; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 68349113688     PISSN: 16602110     EISSN: None     Source Type: Journal    
DOI: 10.1159/000232600     Document Type: Article

References (39)

1. Iseki K, Nakai S, Shinzato T, et al: Prevalence and determinants of hypertension in chronic hemodialysis patients in Japan. Ther Apher Dialysis 2007; 11: 183-188.
2. Agarwal R: Hypertension and survival in chronic hemodialysis patients -past lessons and future opportunities. Kidney Int 2005; 67: 1-13.
3. Port FK, Hulbert-Shearon TE, Wolfe RA, et al: Predialysis blood pressure and mortality risk in a national sample of maintenance hemodialysis patients. Am J Kidney Dis 1999; 33: 507-517.
4. Foley RN, Parfrey PS, Harnett JD, et al: Impact of hypertension on cardiomyopathy, morbidity and mortality in end-stage renal disease. Kidney Int 1996; 49: 1379-1385.
5. Iseki K, Fukiyama K: Predictors of stroke in patients receiving chronic hemodialysis. Kidney Int 1996; 50: 1672-1675. (Pubitemid 26364274)
6. Iseki K, Shinzato T, Nagura Y, et al: Factors influencing long-term survival in patients on chronic dialysis. Clin Exp Nephrol 2004; 8: 89-97.
7. Kalantar-Zadeh K, Kilpatrick RD, McAllister CJ, et al: Reverse epidemiology of hypertension and cardiovascular death in the hemodialysis population. Hypertension 2005; 45: 811-817.
8. Iseki K, Miyasato F, Tokuyama K, et al: Low diastolic blood pressure, hypoalbuminemia, and risk of death in a cohort of chronic hemodialysis patients. Kidney Int 1997; 51: 1212-1217.
9. Charra B, Calemand E, Ruffet M, et al: Survival as an index of adequacy of dialysis. Kidney Int 1992; 41: 1286-1291.
10. Charra B, Bergstrom J, Scribner BH: Blood pressure control in dialysis patients: Importance of the lag phenomenon. Am J Kidney Dis 1998; 32: 720-724. (Pubitemid 28516300)
11. Degoulet P, Legrain M, Reach I, et al: Mortality risk factors in patients treated by chronic hemodialysis: Report of the Diaphane Collaborative Study. Nephron 1982; 31: 103-110.
12. Lowrie EG, Lew NL: Death risk in hemodialysis patients: The predictive value of commonly measured variables and an evaluation of death rate differences between facilities. Am J Kidney Dis 1990; 15: 458-482.
13. Zimmermann J, Herrlinger S, Pruy A, et al: Inflammation enhances cardiovascular risk and mortality in hemodialysis patients. Kidney Int 1999; 55: 648-658.
14. Iseki K, Tozawa M, Yoshi S, et al: Serum Creactive protein (CRP) and risk of death in chronic dialysis patients. Nephrol Dial and Transplant 1999; 14: 1956-1960.
15. Iseki K, Kawazoe N, Fukiyama K: Serum albumin is a strong predictor of death in chronic dialysis patients. Kidney Int 1993; 44: 115-119.
16. Goodkin DA, Young EW, Kurokawa K, et al: Mortality among hemodialysis patients in Europe, Japan, and the United States: Casemix effects. Am J Kidney Dis 2004; 44(suppl 2):S16-S21.
17. Shinzato T, Nakai S, Akiba T, et al: Report on the annual statistical survey of the Japanese Society for Dialysis Therapy in 1996. Kidney Int 1999; 55: 700-712.
18. Akiba T, Nakai S, Shinzato T, et al: Why has the gross mortality of dialysis patients increased in Japan? Kidney Int 2000; 57(Suppl 74):S60-S65.
19. Iseki K, Nakai S, Shinzato T, et al: Prevalence and determinants of hypertension in chronic hemodialysis patients in Japan. Ther Apher Dialysis 2007; 11: 183-188.
20. Chobanian AV, Bakris GL, Black HR, et al: Seventh report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure. Hypertension 2003; 42: 1206-1252.
21. Iseki K, Fukiyama K: Predictors of stroke in patients receiving chronic hemodialysis. Kidney Int 1996; 50: 1672-1675. (Pubitemid 26364274)
22. Vertes V, Cangiano L, Berman LB, et al: Hypertension in end-stage renal disease. N Engl J Med 1969; 280: 978-981.
23. Lopez-Gomez JM, Villaverde M, Jofre R, et al: Interdialytic weight gain as a marker of blood pressure, nutrition, and survival in hemodialysis patients. Kidney Int 2005; 67(suppl 93):S63-S68. (Pubitemid 40019219)
24. Kurokawa K: Salt, kidney and hypertension: Why and what to learn from genetic analyses? Nephron 2001; 89: 369-376.
25. Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH 2000). Guidelines subcommittee of the Japanese Society of Hypertension. Tokyo, Japan 2000.
26. Khosla UM, Johnson RJ: Hypertension in the hemodialysis patient and the 'lag phenomenon': Insights into pathophysiology and clinical management. Am J Kidney Dis 2004; 43: 739-751.
27. Kalantar-Zadeh K, Block G, Humphreys MH, et al: Reverse epidemiology of cardiovascular risk factors in maintenance dialysis patients. Kidney Int 2003; 63: 793-808. (Pubitemid 36315558)
28. Eknoyan G, Beck GJ, Cheung AK, et al: Effect of dialysis dose and membrane flux in maintenance hemodialysis. N Engl J Med 2002; 347: 2010-2019.
29. Rocco MV, Yan G, Heyka RJ, et al: Risk factors for hypertension in chronic hemodialysis patients: Baseline data from the HEMO study. Am J Nephrol 2001; 21: 280-288.
30. Bakris GL, Williams M, Dworkin L, et al: Preserving renal function and diabetes: A consensus approach. National Kidney Foundation Hypertension and Diabetes Executive Committees Working Group. Am J Kidney Dis 2000; 36: 646-661.
31. Tozawa M, Iseki K, Iseki C, et al: Analysis of drug prescription in patients on chronic hemodialysis. Nephrol Dial Transplant 2002; 17: 1819-1824.
32. Efrati S, Zaidenstein R, Dishy V, et al: ACE inhibitors and survival of hemodialysis patients. Am J Kidney Dis 2002; 40; 1023-1029.
33. Suzuki H, Kanno Y, Sugahara S, et al: Effect of angiotensin receptor blockers on cardiovascular events in patients undergoing hemodialysis: An open-label randomized controlled trial. Am J Kidney Dis 2008; 52: 501-506.
34. Tepel M, Hopfenmueller W, Scholze A, et al: Effect of amlodipine on cardiovascular events in hypertensive haemodialysis patients. Nephrol Dial Transplant 2008; 23: 3605-3612.
35. Toto RD: Improving outcomes in hemodialysis patients: The need for well-designed clinical trial. Am J Kidney Dis 2008; 52: 400-402.
36. Iseki K, Tokuyama K, Shiohira Y, et al: Olmesartan Clinical Trial in Okinawan Patients Under OKIDS Group (OCTOPUS): Design and Methods. Clin Exp Nephrol 2009; 13(2):145-151.
37. Shoji T, Tsubakihara Y, Fujii M, et al: Hemodialysis-hypotension as an independent risk factor for two-year mortality in hemodialysis patients. Kidney Int 2004; 66: 1212-1220.
38. Nakai S, Shinzato T, Sanaka T, et al: The current state of chronic dialysis treatment in Japan (as of December 31, 2001). J Jpn Soc Dial Ther 2003; 36: 1-31.
39. Lopez-Gomez JM, Villaverde M, Jofre R, et al: Interdialytic weight gain as a marker of blood pressure, nutrition, and survival in hemodialysis patients. Kidney Int 2005; 67(suppl 93):S63-S68. (Pubitemid 40019219)